
    
      This is a multicenter, randomised, double-blind, placebo-controlled, phase 3 trial. The main
      purposes of this study are to examine the efficacy and safety of standard chemotherapy plus
      moxifloxacin or placebo as first-line treatment in patients with metastatic triple-negative
      breast cancer. This study is designed to recruit up to 228 subjects.
    
  